DT MedTech said it acquired the Hintermann lower extremities assets for an undisclosed amount, including the H3 total ankle replacement and revision system and the Kalix II implant designed to treat flat-foot deformities.
Baltimore-based DT MedTech said the deal also includes a system for patients cobalt-chrome sensitivities, plus the instrumentation and consumables for the implants, which were developed by Dr. Beat Hintermann of Switzerland’s Kantonsspital Liestal and the University of Basel.
“Our ownership of this superior, clinically-proven line of the Hintermann Series medical devices marks an important milestone for DT MedTech, as we begin to position ourselves as a global leader in lower extremity surgical solutions. Working diligently alongside Prof. Beat Hintermann, we plan to expand worldwide distribution of the Hintermann Series H3 total ankle replacement and will introduce Prof. Hintermann’s innovative, 2-piece total ankle replacement device in the very near future. We want to assure all surgeons who currently use these products that the newly acquired devices will remain exactly the same in structure and materials. Additionally, we foresee no disruption in terms of product availability,” DT Medtech president & CEO Dr. David Reicher said in prepared remarks.
The company said it plans to continue to use the current roster of manufacturers that’s already making the Hintermann devices after it takes over May 1, with Healthlink Europe keeping logistics handling duties outside the U.S.